Robert Barrow

CIK 1897557 · Chief Executive Officer · last filed 2026-06-26

Robert Barrow is a Chief Executive Officer who has filed 51 SEC Form 4 insider transactions across 2 companies since 2022. The most recent filing shows the insider sold $1.3M of DFTX on Jun 26, 2026. Across all open-market trades the lifetime net is −$3.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $48.8M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$48.75M

Companies

2

Total Filings

51

Lifetime Open-Market Net

-$3.54M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DFTX Chief Executive Officer 1,098,246 $44.39 $48.75M -$1.77M 4 2026-06-26
Definium Therapeutics, Inc. (MNMD) Delisted Chief Executive Officer 778,477 $15.00 $11.68M -$1.77M 35 2025-12-29

Recent Filings

51 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-26 DFTX Sell (S) −29,208 -$1.32M EDGAR
2026-06-25 DFTX Notice (144) −29,208 -$1.23M EDGAR
2026-06-22 DFTX Grant (A) +375,000 $0 EDGAR
2026-03-26 DFTX Sell (S) −24,431 -$451.2K EDGAR
2026-03-25 DFTX Notice (144) −24,431 -$451.2K EDGAR
2026-02-05 DFTX Grant (A) +320,000 $0 EDGAR
2025-12-29 Definium Therapeutics, Inc. (MNMD) Delisted Sell (S) −25,791 -$339.1K EDGAR
2025-12-29 DFTX Notice (144) −25,791 -$339.1K EDGAR
2025-09-26 Definium Therapeutics, Inc. (MNMD) Delisted Sell (S) −25,797 -$252.0K EDGAR
2025-09-25 DFTX Notice (144) −25,797 -$252.1K EDGAR
Showing 110 of 51
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.